Navigation Links
New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers
Date:7/1/2008

The first oral, broad-spectrum angiogenesis inhibitor, specially formulated through nanotechnology, shows promising anticancer results in mice, report researchers from Children's Hospital Boston. Findings were published online on June 29 by the journal Nature Biotechnology.

Because it is nontoxic and can be taken orally, the drug, called Lodamin, may be useful as a preventive therapy for patients at high risk for cancer or as a chronic maintenance therapy for a variety of cancers, preventing tumors from forming or recurring by blocking the growth of blood vessels to feed them. Lodamin may also be useful in other diseases that involve aberrant blood-vessel growth, such as age-related macular degeneration and arthritis.

Developed by Ofra Benny, PhD, in the Children's laboratory of the late Judah Folkman, MD, Lodamin is a novel slow-release reformulation of TNP-470, a drug developed nearly two decades ago by Donald Ingber, MD, PhD, then a fellow in Folkman's lab, and one of the first angiogenesis inhibitors to undergo clinical testing. In clinical trials, TNP-470 suppressed a surprisingly wide range of cancers, including metastatic cancers, and produced a few complete remissions. Trials were suspended in the 1990s because of neurologic side effects that occasionally occurred at high doses, but it remains one of the broadest-spectrum angiogenesis inhibitors known.

Lodamin appears to retain TNP-470's potency and broad spectrum of activity, but with no detectable neurotoxicity and greatly enhanced oral availability. While a number of angiogenesis inhibitors, such as Avastin, are now commercially available, most target only single angiogenic factors, such as VEGF, and they are approved only for a small number of specific cancers. In contrast, Lodamin prevented capillary growth in response to every angiogenic stimulus tested. Moreover, in mouse models, Lodamin reduced liver metastases, a fatal complication of many cancers for which
'/>"/>

Contact: Bess Andrews
elizabeth.andrews@childrens.harvard.edu
617-919-3110
Children's Hospital Boston
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Study finds blocking angiogenesis signaling from inside cell may lead to serious health problems
2. New inhibitor has potential as cancer drug
3. New research shows no link between aromatase inhibitors and cardiovascular problems
4. New partnership offers outsourced R&D in membrane biology
5. Census of protein architectures offers new view of history of life
6. NAS report offers new tools to assess health risks from chemicals
7. New class of drug offers hope to treatment-resistant AIDS patients
8. Darwin Symposium at Field Museum offers broad overview of his science and its impact
9. Conference on healthspan offers new opportunities for interdisciplinary collaboration
10. Protein controls blood vessel formation, offers new drug target
11. Genetic breakthrough offers promise in tackling kidney tumors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers
(Date:9/18/2014)... millions of Americans to undertake jaunts into the countryside each ... longer within a century, according to new research. , Climate ... the United States as summer temperatures linger later into the ... Ecology and Biogeography . For instance, the paper birch ... New Hampshire could change color one to three weeks ...
(Date:9/18/2014)... 18, 2014 -- Arizona turned its newborn screening program into ... short months, earning it the first-ever Newborn Screening Quality Award ... Dimes presented Will Humble, M.P.H., Arizona,s Department of Health Services ... Mr. Humble established a policy of full transparency for the ... blood samples to the lab for analysis, and set a ...
(Date:9/18/2014)... which have devastated algal forests in the eastern Mediterranean ... basin if their distribution continues to expand as the ... an international team of researchers led by Dr Adriana ... the Mediterranean Institute for Advanced Studies in Spain, is ... of the team surveyed more than 1000 kilometres of ...
Breaking Biology News(10 mins):Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Tropical fish a threat to Mediterranean Sea ecosystems 2
... A new cheetah study by the Wildlife Conservation Society and ... litters have more than one father. While promiscuity in ... the Wildlife Conservation Society and the Zoological Society of London ... with the wandering eye, as reported in a paper in ...
... new species of aeolid nudibranchs discovered in the ... discrete biogeographic region that has an extremely high ... to yield a wealth of never-before-described marine animals ... Institute in Panama. Alicia Hermosillo, researcher at the ...
... a significantly faster rate than projected by even the ... research, by scientists at the National Center for Atmospheric ... and Ice Data Center (NSIDC), shows that the Arctic's ... any of the 18 computer models used by ...
Cached Biology News:Philandering female felines forgo fidelity 2Scientists discover 5 new species of sea slugs from the Tropical Eastern Pacific 2Arctic ice retreating more quickly than computer models project 2Arctic ice retreating more quickly than computer models project 3
(Date:9/19/2014)... Paul, Minnesota (PRWEB) September 19, 2014 ... from related food industries will gather October 5–8, ... at the Rhode Island Convention Center in Providence, ... will feature the work of food scientists, chemists, ... quality control, and food production management. To date, ...
(Date:9/18/2014)... HealthTronics, Inc ., a ... products and services, announced that a poster related ... versus external beam radiotherapy (EBRT) is being presented ... Association (MAAUA) Annual Meeting in Baltimore, Maryland September ... Cryosurgery and External Beam Radiation as Treatments for ...
(Date:9/18/2014)... , September 18, 2014 ... ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the ... - Global Strategic Business Report" ... http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the worldwide ... Million by the following Product Segments: ...
(Date:9/18/2014)... Research and Markets has announced ... Report 2014" report to their offering. ... a professional and in-depth study on the current state ... report provides a basic overview of the industry including ... albumin market analysis is provided for the international markets ...
Breaking Biology Technology:Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3
... 27 DHA omega-3 innovator,Martek Biosciences announced today that ... featured in new Ricos(R) Cheese Sauce.,Sold to schools throughout ... of,DHA per serving in the standard foodservice packaging of ... 3.5 oz. single serve cup which contains 50 mg,of ...
... III Development and ... -, NEW YORK, and PRINCETON, N.J., Aug. 27 ... Company (NYSE: BMY ) ("companies"),today announced that they ... research, develop and commercialize DGAT-1,inhibitors, a collaboration first announced ...
... launched today a new 200 mg single-use vial ... who have,adjuvant stage III colon cancer and advanced ... efficiency and safety in the,preparation of the injectable ... mg and 100 mg single- use vials. The ...
Cached Biology Technology:life'sDHA(TM) Featured in New Ricos(R) Cheese Sauce 2life'sDHA(TM) Featured in New Ricos(R) Cheese Sauce 3Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program 2Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program 3Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program 4New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 2New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 3New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 4New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 5New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 6New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 7
... Target Retrieval Solution, High pH This ... target retrievel prior to immunohistochemical staining procedures. ... tissue sections mounted on glass slides. For ... 9.9, is especially effective. It should be ...
... very potent Rnase free Ribonuclease ... a broad range of temperatures ... does not inhibit SP6, T7, ... and M-MLV reverse transcriptase or ...
... Dako Target Retrieval Solution, pH 9 ... Tris/EDTA buffer, pH 9, intended for heat-induced ... It is well-suited for use on formalin-fixed, ... Compared with 0.01 mol/L citrate buffer, pH ...
... SeMet White to off-white solid. Increases ... by HPLC. Soluble in H 2 O. ... to use. RTECS EK7713840, CAS 3211-76-5, M.W. ... 13, 8515.Jornot, L., and Junod, A.F. 1995. ...
Biology Products: